页 1 从 141 结果
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates generally to a method for treatment of skin lesions and internal wounds such as viable but underperfused myocardium. More specifically, this invention is related to a method for treatment of a subject afflicted with
This invention is concerned with novel 3,4-dihydrospiro-2H-1,3-benzoxazines having therapeutic utility, processes for their preparation, methods of treating inflammation, edema and autoimmune diseases, and novel pharmaceutical formulations comprising at least one of the novel compounds as active
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is a national phase application of PCT Application No. PCT/KR2015/002640, filed on Mar. 18, 2015, which claims the benefit and priority to Korean Patent Application No. 10-2014-0031624, filed Mar. 18, 2014. The entire disclosures of the
TECHNICAL FIELD
The present invention relates to a composition for treating inflammatory brain diseases, comprising stem cells as an active ingredient.
BACKGROUND ART
Stem cells refer to cells having the ability to self-replicate and the ability to differentiate into at least two cells and can be
GOVERNMENTAL SUPPORT
Research support for the present invention was provided by U.S. Public Health Service NHLB Grants Numbers HL16714 and HL33104.
FIELD OF THE INVENTION
The present invention is concerned with inflammatory and non-inflammatory associated edemas and is particularly directed to
FIELD OF THE INVENTION
The present invention is concerned with inflammatory and non-inflammatory (hydraulic) associated edemas and is particularly directed to prophylactic and therapeutic methods for treating localized and systemic edemas caused or mediated by interleukins.
BACKGROUND OF THE
FIELD OF THE INVENTION
This invention generally relates to a method of inhibiting an inflammatory response of skin or mucosal membranes to injury, and more particularly to the use certain neuropeptides, particularly of Corticotropin Releasing Factor and its analogs, in attenuating inflammation of
CROSS-REFERENCES TO RELATED APPLICATIONS
This application is a U.S. national phase application of International PCT Patent Application No. PCT/KR2011/006094, which was filed on Aug. 18, 2011, which claims priority to Korean Patent Application Nos. 10-2010-0123086, filed Dec. 3, 2010;
This invention relates to novel imidazothiazole derivatives, their salts, a method for the production thereof, and anti-inflammatory compositions containing the same. More particularly, this invention relates to 2,3-di-substituted-5,6-dihydroimidazo [2,1-b] thiazole, its salts, a method for the
This invention relates to novel imidazothiazole derivatives, their salts, a method for the production thereof, and anti-inflammatory compositions containing the same. More particularly, this invention relates to 2,3-di-substituted-5,6-dihydroimidazo [2,1-b] thiazole, its salts, a method for the
N-nicotinoylhalogenobenzoguanamines are known in the art to exhibit strong anti-inflammatory action (see Japanese patent application No. 56-87124). It has now been discovered that triazine derivatives of the formula (I): ##STR2## and pharmaceutically acceptable salts thereof wherein R.sup.1 and
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates to a method for treating inflammatory or degenerative diseases by administering to an individual a pharmaceutically effective amount of a mixed extract of Cibotii Rhizoma, Ledebouriellae Radix, Achyranthis Radix,
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates to the use of plasminogen activator as an anti-inflammatory agent.
2. Description of the Related Art
Plasminogen activators play an important physiological role in the regulation of thrombolysis. This action is
FIELD OF THE INVENTION
The invention relates to the field of pathological angiogenesis and arteriogenesis. In particular, the invention describes a stress-induced phenotype in a transgenic mouse (PIGF-) that does not produce Placental Growth Factor (PIGF) and that demonstrates an impaired vascular
FIELD OF THE INVENTION
This invention is related to the use of leukemia inhibitory factor (LIF) and other agonists of the LIF receptor, in the regulation of inflammation and pain.
BACKGROUND
Leukemia inhibitory factor (LIF) belongs to the neuropoietic cytokine family, which also includes ciliary